secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0000014272-23-000179
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers Q3 rev $10.97B; GAAP EPS $0.93, non-GAAP $2.00; Mirati acquisition
--------------------------------------------------------------------------------

- Q3 revenues $10,966M, down 2% YoY (3% ex-FX); GAAP EPS $0.93 (+24%), non-GAAP EPS $2.00 (+1%).
- In-line and new product portfolio revenue grew 8% YoY (7% ex-FX).
- Acquired IPRD and licensing charges reduced GAAP and non-GAAP EPS by $0.03 per share.
- Planned acquisition of Mirati Therapeutics to strengthen oncology pipeline; terms not disclosed.
- Adjusted 2023 GAAP EPS guidance downward; raised midpoint of non-GAAP EPS guidance range.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/0000014272-23-000179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/bmy-20231026.htm
  HTML page:      https://secwatch.observer/filing/0000014272-23-000179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer